Background Image

Latest News

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

15 January 2020

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial and therapeutic expertise 

Dr. Howd has over 20 years’ experience in the life science sector. He has held various private and public company Executive and Board roles in the UK, EU and USincluding ImmunocorePoseida TherapeuticsViamet and MalinAs CEO of Malin, he led equity capital raises totalling EUR 430and implemented the operational and strategic refinement and priority asset focus for the company.  

Prior to this, Dr. Howd also held numerous investment andfinance roles within global financial institutions. He received his PhD in Neuroscience from St. Thomas’s Hospital, University of London and undertook a postdoctoral fellowship at the National Institutes of Health, Bethesda Maryland. 

Andrew Kay, Chairman, said: “We are delighted to welcome Adrian to our Board and I am certain he will provide Blueberry Therapeutics with solid counsel. He has a proven track record of working with fast growing companies, including those witdermatology and anti-infective focus 

“Adrian’s experience of senior Executive and Board roles and numerous investment and financing roles will help to drive the company forward and achieve our continued success. 

Adrian Howd, NED, said: “I am delighted to be joining Blueberry Therapeutics, a company with novel technology and a pipeline of drugs with clear pathways to commercialisation. I welcome the opportunity to work alongside Chairman Andrew Kay and a highly experienced Board and management team at this exciting time in the company’s evolution.”